Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Valeriy Krylov"'
Autor:
Ilya Klabukov, Peter Shegay, Alexey Leontyev, Denis Baranovskii, German Davydov, Marina Poluektova, Lyudmila Grivtsova, Vasily Petriev, Valeriy Stepanenko, Igor Gulidov, Valeriy Krylov, Svetlana Osadchaya, Vladimir Petrov, Maria Sedova, Mikhail Vekilyan, Olga Krasilnikova, Sergey Morozov, Sergey Ivanov, Andrey Kaprin
Publikováno v:
Current Radiopharmaceuticals. 16:243-252
Objective: Previously, low-dose radiation therapy was used for pneumonia treatment. We aimed to investigate the safety and effectiveness of carbon nanoparticles labeled with Technetium isotope (99mTc) in a form of ultradispersed aerosol in combinatio
Autor:
Igor K. Khvostunov, Elena Nasonova, Valeriy Krylov, Andrei Rodichev, Tatiana Kochetova, Natalia Shepel, Olga Korovchuk, Polina Kutsalo, Petr Shegai, Andrei Kaprin
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 6; Pages: 5128
The risk of toxicity attributable to radioiodine therapy (RIT) remains a subject of ongoing research, with a whole-body dose of 2 Gy proposed as a safe limit. This article evaluates the RIT-induced cytogenetic damage in two rare differentiated thyroi
Autor:
Tatiana Kochetova, Valeriy Krylov, Mihail Sigov, Karina Petrosyan, Andrey Shuriniv, Artem Pronin
Publikováno v:
6th International Conference on Radiopharmaceutical Therapy (ICRT 2021) Abstracts.
Autor:
Tatiana Kochetova, Valeriy Krylov, Andrey Kaprin, Sergey Ivanov, Karina Petrosyan, Andrey Shurinov
Publikováno v:
6th International Conference on Radiopharmaceutical Therapy (ICRT 2021) Abstracts.
Autor:
Valeriy Krylov, Andrey Kaprin, Dmitriy Fomin, Bozhenko Vk, O. Avilov, Feliks Sevryukov, Vladimir Solodkiy, Stefan Ivanov, Yekaterina Dzhikiya, Timur Izmaylov, Yu. Blanter
Publikováno v:
Problems in oncology. 65:83-87
Recently, there has been an increase in the incidence and detectability of patients with differentiated thyroid cancer. At the same time in a number of patients in the combined treatment, initially low susceptibility of regional metastases to radioio
Autor:
Valeriy Krylov, Tatiana Kochetova
Publikováno v:
Pakistan Journal of Nuclear Medicine. :38-41
Ra-223 therapy is recommended for Castration Resistant Prostate Cancer (CRPC) patients with bone metastases. The standard protocol is 5-6 cycles of therapy with 4 weeks intervals to gain survival benefit. We report a case of a chemo-naive CRPC patien
Publikováno v:
ResearcherID
Scopus-Elsevier
Scopus-Elsevier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::199a72d80a9fb9206c7071e1188d664a
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=MEDLINE&KeyUT=MEDLINE:26016139&KeyUID=MEDLINE:26016139
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=MEDLINE&KeyUT=MEDLINE:26016139&KeyUID=MEDLINE:26016139